Breast Cancer Clinical Trial
Official title:
A Phase I Study of CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer
The goal of this phase I clinical study is to find the highest safe dose of gemcitabine and CT-2103 that can be given in combination for the treatment of metastatic breast cancer. The safety and effectiveness of this combination will also be studied. This clinical trial will be offered to patients who are being considered for treatment with gemcitabine. Research lab samples and research biopsies will not be requested as part of this study.
CT-2103 is a chemotherapy drug designed to deliver an active chemotherapy medication
(paclitaxel) inside of tumor cells. Gemcitabine is FDA approved for the treatment of breast
cancer.
Before you can start receiving drug on this study, you will have what are called "screening
tests." These tests will help the doctor decide if you are eligible to take part in the
study. You will have a complete medical history and physical exam. You will have a CT scan
of the chest and abdomen, a bone scan, and a chest x-ray performed to document the size and
location of the tumor(s). Blood (about 2 tablespoons) will be drawn for routine tests. Women
who are able to have children must have a negative blood-pregnancy test.
If you are found to be eligible to take part in this study, you will be assigned to a dose
of CT-2103. Participants in this study will be enrolled in groups of 3. The first group will
receive the lowest dose of CT-2103. Each new group of patients will receive a higher dose
until the highest safe dose is found. The dose that you receive will depend on how many
patients have received CT-2103 before you. You will only be assigned to one dose level, and
you will stay at this same dose level for the entire study unless you have a serious side
effect that requires the dose to be decreased or stopped. All participants will receive the
same dose of gemcitabine, though it too may be lowered if severe side effects occur.
Both CT-2103 and gemcitabine are given through a vein. On the first day of your therapy
(called 'Day 1'), you will receive a routinely given medication, ondansetron (Zofran), that
will help decrease the risk of nausea. About 30 minutes later, CT-2103 will be given over
10-20 minutes followed by gemcitabine over 30 minutes.
One week later ('Day 8'), you will receive gemcitabine through the vein over about 30
minutes. You will return to see your doctor 3 weeks after your first dose of chemotherapy
('Day 21'), and then this pattern or cycle of treatment will be given again.
You will continue on therapy as long as the cancer is being controlled and you are not
having unexpected or intolerable side effects. All chemotherapy will be given at M. D.
Anderson.
You will have blood (about 2 tablespoons) collected once a week while you are on study to
monitor the effects of chemotherapy on your bone marrow and liver and kidney function. You
will see your doctor every 3 weeks to monitor how you are tolerating the therapy. At these
visits, your doctor will discuss any symptoms you are having, and you will have a physical
exam. If you are taking warfarin (Coumadin) you will need to have blood (about 1 tablespoon)
collected three times a week to monitor you warfarin levels.
After each 6 weeks of chemotherapy, you will have repeat scans to evaluate the effects of
the study drugs upon your cancer.
Once you have stopped taking therapy with CT-2103 and gemcitabine, you will be asked to
return to see your physician in about 6 weeks to evaluate how you are doing and to find out
if there has been any additional change in the cancer. You will have a complete medical
history and physical exam. You will have a CT scan of the chest and abdomen, a bone scan,
and a chest x-ray performed to document the size and location of the tumor(s).
This is an investigational study. Gemcitabine is FDA approved for the treatment of breast
cancer when given in combination with paclitaxel. Gemcitabine will not be provided free of
charge. CT-2103 is not yet FDA approved and will be provided free of charge during the
study. Any laboratory testing that is not standard of care will be paid for by the
supporting company. About 18 women will take part in this study. All will be enrolled at M.
D. Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |